Skip to main content
. Author manuscript; available in PMC: 2018 May 4.
Published in final edited form as: Cell Stem Cell. 2017 Mar 30;20(5):706–719.e7. doi: 10.1016/j.stem.2017.03.002

Figure 6. DUSP9 overexpression establishes a female-like proteome and signaling state in male ESCs.

Figure 6

(A) Western blot analyses for p-ERK and ERK, p-MEK and MEK in isogenic XX and XY ESCs (left) and in Dusp9-overexpressing cells (right). See Figure S7A for quantification.

(B) Expression of targets of ERK, GSK and AKT pathways in XY (blue) and XX (red) ESCs as well as Dusp9-overexpressing KH2 cells treated with doxycycline (pink) using proteomics data (2 replicates per line).

(C) Model to explain dose-dependent regulation of MAPK/GSK/AKT pathways, pluripotency and epigenetic factors by DUSP9.

(D) Venn diagram of differentially expressed proteins (>1.5-fold) between male and female ESCs (blue) and between wild-type, male ESCs and Dusp9-overexpressing, male ESCs (grey). Examples of overlapping proteins are indicated by an arrow.

(E) Expression of ated by an arrow.

(E) Expression of proteins associated with naïve and primed pluripotency along with DUSP factors in XY (blue) and XX (red) ESCs as well as Dusp9-overexpressing KH2 ESCs treated with doxycycline (pink) using proteomics data (2 replicates per line).

(F) Western blot analysis for DNMT1, DNMT3A, DNMT3B and DNMT3L levels in Dusp9-overexpressing KH2 cells treated with or without doxycycline. A Dnmt1/3a/3b triple knock-out (TKO) male ESC line and wild-type XX and XY ESC lines were included as controls. See Figure S7B for quantification.

See also Figure S7 and Table S1 and 6.